Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Shanghai Zheye Biotechnology describes new anticancer compounds

Feb. 28, 2022

Chinese investigators identify new PI3Kdelta inhibitors

Feb. 25, 2022

Beijing Jacobio Pharmaceuticals presents new glutaminase inhibitors

Feb. 25, 2022

Jazz Pharmaceuticals synthesizes new Raf kinase inhibitors

Feb. 25, 2022

Foghorn Therapeutics divulges new PROTACs

Feb. 25, 2022

Bayer and collaborators patent CSNK1 inhibitors

Feb. 25, 2022

Evaluating effect of LyeTxI-b on colorectal cancer using chicken chorioallantoic membrane model

Feb. 25, 2022

Adorx Therapeutics discloses adenosine receptor A2A and/or A2B antagonists

Feb. 24, 2022

Sanofi patents YAP1/TAZ and TEAD interaction inhibitors

Feb. 24, 2022

Actinium and AVEO collaborate to develop novel Ac-225 ErbB3-targeted radiotherapy

Feb. 23, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...